Industry News
2014 ASI Annual Scientific Meeting
The ASI Annual Scientific meeting has joined forces with several clinically oriented societies this year to bring bench and bedside researchers together for one big immunological event. [ + ]
Global Kinetics gets FDA clearance for PKG
Global Kinetics has been cleared to sell the Australian-made Parkinson's KinetiGraph wearable symptom monitoring device in the US.
[ + ]AusBiotech calls for nominations to the board of directors
Further to the notice of the forthcoming election for AusBiotech's board of directors, nominations are now open for eligible AusBiotech members.
[ + ]Virax seeks to reactivate IND for cancer drug
Virax (ASX:VHL) has received a technical assessment that will allow it to start the process of reactivating the US IND application for cancer drug GGTI-2418.
[ + ]Iluvien approved in 10th EU market: pSivida
pSivida (ASX:PVA) licensee Alimera Sciences has got the marketing nod in Sweden for DMO treatment Iluvien, marking its 10th EU approval.
[ + ]2014 Australian Museum Eureka Prizes announced
The 2014 Australian Museum Eureka Prize winners were announced at an award dinner held last night at Sydney Town Hall. The national awards, which have been running since 1990, acknowledge outstanding contributions to Australian science. [ + ]
Bronchitol effective in high-risk bronchiectasis patients
Pharmaxis' (ASX:PXS) Bronchitol may have missed its main endpoint in last year's bronchiectasis trial, but new analysis shows a statistically significant improvement in high-risk patients. [ + ]
Coffee genome sequenced
An international research effort into the genome sequencing of the coffee plant has revealed its 'convergent evolution' with unrelated cacao and tea plants.
[ + ]Patents enabling and supporting medical research and resulting tests, vaccines and treatments
Patents are at the core of enabling genetic tests, treatments, vaccines and cures resulting from medical research, says AusBiotech - contrary to reports stemming from last week's Federal Court decision in the D'Arcy v Myriad Genetics case that claim research is being stifled.
[ + ]Ascend to begin breast cancer, BCC trials in '15
Ascend Biopharmaceuticals aims to commence a phase II trial of BCC treatment candidate ASN-002 in 1H15 and a phase Ib trial of breast cancer candidate ASN-004 in 2H15.
[ + ]Australian scientist re-elected to international science council
Professor David Black has been re-elected as Secretary General of the International Council for Science. [ + ]
The first far ultraviolet spectra of a cometary surface
NASA's Alice ultraviolet (UV) spectrograph, located aboard the European Space Agency's Rosetta comet orbiter, has made the first far ultraviolet spectra of a cometary surface. [ + ]
Antisense's ATL1103 shows promise in acromegaly
Antisense Therapeutics' (ASX:ANP) ATL1103 candidate reduced sIGF-I levels in patients with the growth disorder acromegaly during a phase II trial.
[ + ]Federal court upholds decision on Myriad patent
The Federal Court of Australia has upheld its decision from last year in favour of Myriad Genetics patenting isolated DNA associated with breast cancer gene mutations. [ + ]
Support for Chief Scientist's STEM report
Australia's Chief Scientist, Professor Ian Chubb, has released his recommendations for a strategic approach to science and its related fields. [ + ]